Free Trial

Beta Bionics (NASDAQ:BBNX) Now Covered by Truist Financial

Beta Bionics logo with Medical background

Truist Financial assumed coverage on shares of Beta Bionics (NASDAQ:BBNX - Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $26.00 target price on the stock.

A number of other equities analysts have also recently commented on BBNX. The Goldman Sachs Group began coverage on Beta Bionics in a report on Friday, May 30th. They issued a "neutral" rating and a $16.00 target price for the company. Robert W. Baird began coverage on Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective for the company. Piper Sandler began coverage on Beta Bionics in a report on Monday, February 24th. They set an "overweight" rating and a $26.00 price objective for the company. Stifel Nicolaus began coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Leerink Partnrs upgraded Beta Bionics to a "strong-buy" rating in a report on Monday, February 24th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $23.44.

View Our Latest Stock Analysis on BBNX

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded down $0.45 on Monday, reaching $17.78. The company had a trading volume of 317,195 shares, compared to its average volume of 530,150. The firm's 50-day simple moving average is $14.37. Beta Bionics has a 1 year low of $8.89 and a 1 year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Insiders Place Their Bets

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the sale, the chief financial officer now directly owns 45,503 shares in the company, valued at approximately $814,048.67. This represents a 3.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 4,519 shares of company stock worth $80,845.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently made changes to their positions in BBNX. Rhumbline Advisers purchased a new stake in shares of Beta Bionics in the 1st quarter worth $158,000. Evanson Asset Management LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth $475,000. Bank of New York Mellon Corp purchased a new stake in shares of Beta Bionics during the 1st quarter worth $316,000. Values First Advisors Inc. purchased a new stake in shares of Beta Bionics during the 1st quarter worth $457,000. Finally, Jennison Associates LLC purchased a new stake in shares of Beta Bionics during the 1st quarter worth $828,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

See Also

Analyst Recommendations for Beta Bionics (NASDAQ:BBNX)

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines